Stifel Financial
ARQT icon

Stifel Financial’s Arcutis Biotherapeutics ARQT Stock Holding History

Stifel Financial’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-79,805
Closed -$1.5M – 3572
2025
Q3 		$1.5M Sell
79,805
-10,386
-12% -$164K ﹤0.01% 2114
2025
Q2 		$1.26M Buy
+90,191
New +$1.26M ﹤0.01% 2171
2020
Q4 		– Sell
-23,748
Closed -$696K – 3036
2020
Q3 		$696K Buy
23,748
+2,921
+14% +$78K ﹤0.01% 1877
2020
Q2 		$630K Buy
20,827
+891
+4% +$25.8K ﹤0.01% 1871
2020
Q1 		$594K Buy
+19,936
New +$536K ﹤0.01% 1758

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Stifel Financial's ARQT Position: Q4 2025 in Review

Stifel Financial sold out of Arcutis Biotherapeutics (ARQT) in Q4 2025, closing a stake of 79,805 shares — an estimated $1.5M sold.

Stifel Financial first reported a position in ARQT in Q1 2020 and held it in 5 quarters. The position peaked at $1.5M in Q3 2025. 283 funds tracked by Wall St. Rank hold ARQT as of Q4 2025.

  • Stifel Financial reported no remaining Arcutis Biotherapeutics position as of Q4 2025 after selling out during the quarter.
  • Stifel Financial sold 79,805 Arcutis Biotherapeutics shares in Q4 2025, an estimated $1.5M.
  • Stifel Financial first reported a position in Arcutis Biotherapeutics in Q1 2020 and held it in 5 quarters.
  • Stifel Financial's Arcutis Biotherapeutics position peaked at $1.5M in Q3 2025.
  • 283 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q4 2025.

Based on Stifel Financial's 13F filing for Q4 2025, filed 13 Feb 2026.